Shares of Apogee Therapeutics, Inc. (APGE) touched a new high of $82.90 yesterday, marking a significant rebound from their 52-week low of $26.20 set last April.
Apogee is a clinical-stage biotechnology company advancing differentiated biologics for inflammatory and immune-mediated diseases with high unmet need.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com